Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.
Hayden Mitteer, PharmD Candidate
Advertisement
Articles by Hayden Mitteer, PharmD Candidate
Advertisement
Latest Updated Articles
Eculizumab and Other Therapies for the Treatment of High-Risk Transplant-Associated Thrombotic MicroangiopathyPublished: October 3rd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
2
Addressing Drug Resistance in Lung Cancer
3
From Mutation to Medicine: Targeted Therapies in Lung Cancer
4
Expert Discusses Early Safety and Tolerability Findings for VMT-α-NET in Neuroendocrine Tumors | ESMO 2025
5
